Suppr超能文献

吉诺通用于急慢性鼻窦炎:系统评价与荟萃分析方案

Gelomyrtol for acute or chronic sinusitis: A protocol for systematic review and meta-analysis.

作者信息

Wu Yongcan, Wang Xiaomin, Huang Demei, Pei Caixia, Li Shuiqin, Wang Zhenxing

机构信息

Department of Respiratory Medicine.

Department of Geriatrics.

出版信息

Medicine (Baltimore). 2020 Jun 5;99(23):e20611. doi: 10.1097/MD.0000000000020611.

Abstract

BACKGROUND

Sinusitis is a common condition worldwide, significantly affecting the quality of life of patients. Due to the limitations of conventional medicines, such as serious side effects and low efficacies, Gelomyrtol may be a promising treatment for sinusitis. As no related systematic review has been published, the purpose of this study will be to evaluate the safety and efficacy of Gelomyrtol for acute or chronic sinusitis.

METHODS

PubMed, EMBASE, the Cochrane Library, the Web of Science, the Chinese National Knowledge Infrastructure Database, the Chinese Biomedical Literature Database, the Wan Fang Database, and the Chongqing VIP Chinese Science, and Technology Periodical Database will be searched from their commencement until July 2020. Randomized controlled trials of Gelomyrtol for acute or chronic sinusitis will be selected in any language. Primary outcomes will include the Sino-Nasal Outcome Test-22 (SNOT-22) score, quality of life score as measured by SF-36, and the change in computed tomography (CT) score. Study selection, data extraction, and deviation risk assessment will be carried out by 2 investigators independently. RevMan V.5.3 software will be used to analyze the study data.

RESULTS

The study will provide high-quality evidence for estimating the efficacy and safety of Gelomyrtol in the treatment of acute or chronic sinusitis.

CONCLUSIONS

This systematic review will explore whether Gelomyrtol is an effective and safe intervention in the treatment of acute or chronic sinusitis.

ETHICS AND DISSEMINATION

As no patient data will be used in this study, ethical approval will not be required. The review will be published as an article or a conference presentation in a peer-reviewed journal.

REGISTRATION

OSF registration number: DOI 10.17605/OSF.IO/MTEU2.

摘要

背景

鼻窦炎在全球范围内是一种常见疾病,严重影响患者的生活质量。由于传统药物存在局限性,如严重的副作用和低疗效,吉诺通可能是一种有前景的鼻窦炎治疗药物。由于尚未发表相关的系统评价,本研究的目的是评估吉诺通治疗急性或慢性鼻窦炎的安全性和有效性。

方法

检索PubMed、EMBASE、Cochrane图书馆、科学引文索引、中国知网数据库、中国生物医学文献数据库、万方数据库和重庆维普中文科技期刊数据库,检索时间从建库至2020年7月。将选取任何语言发表关于吉诺通治疗急性或慢性鼻窦炎的随机对照试验。主要结局将包括鼻窦结局测试-22(SNOT-22)评分、用SF-36测量的生活质量评分以及计算机断层扫描(CT)评分的变化。研究筛选、数据提取和偏倚风险评估将由2名研究者独立进行。将使用RevMan V.5.3软件分析研究数据。

结果

本研究将为评估吉诺通治疗急性或慢性鼻窦炎的疗效和安全性提供高质量证据。

结论

本系统评价将探讨吉诺通在治疗急性或慢性鼻窦炎方面是否为一种有效且安全的干预措施。

伦理与传播

由于本研究不使用患者数据,因此无需伦理批准。该评价将作为一篇文章或在同行评审期刊上的会议报告发表。

注册

开放科学框架(OSF)注册号:DOI 10.17605/OSF.IO/MTEU2。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30a4/7306384/eca04d00cc71/medi-99-e20611-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验